Suppr超能文献

Ki-67 增殖指数和肝转移的存在可将接受切除术的胰腺神经内分泌肿瘤(pNEN)分为不同的进展风险级别。

Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.

机构信息

Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.

Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, Milan, Italy.

出版信息

Eur J Surg Oncol. 2019 May;45(5):755-760. doi: 10.1016/j.ejso.2018.10.052. Epub 2018 Oct 11.

Abstract

In pancreatic neuroendocrine neoplasms (pNEN), size ≤2 cm and Ki-67 < 3% suggest indolent behavior, but no factor alone predicts prognosis. We investigated factors predictive of tumor progression in 80 pNENs surgically resected in a single Institution from 1995 to 2015. At multivariable analysis the only two independent variables related to PFS were Ki-67 (HR 2.97; 95%CI 1.26-7.02) and presence of synchronous liver metastases (HR 3.60; 95%CI 1.70-7.61). Using Ki-67 < 3% and M0 as reference, the HR for tumor progression was 3.21 (95%CI 1.18-8.74) for M0 patients with Ki-67 3-20%, 5.06 (2.29-11.2) for M1 patients with Ki-67 ≤ 20% and 24.3 (6.64-89.2) for those with Ki-67 > 20%. Tumor size (≤2 vs. >2 cm) was not a predictive factor at any analysis. Intra-class correlation of Ki-67 values on pre-surgical biopsies vs. surgical specimens was 0.99 and Ki-67 classes were correctly identified in 97% of biopsies. Ki-67 and presence of liver metastases are the major prognostic factors in pNEN and identify different progression risks regardless of tumor size. Pre-surgical pNEN biopsy for Ki-67 assessment should be included in the evaluation of patients with 1-2 cm tumors to help in the decision on whether to perform surgical resection.

摘要

在胰腺神经内分泌肿瘤(pNEN)中,直径≤2cm 且 Ki-67<3%提示肿瘤生长缓慢,但没有任何单一因素可以预测预后。我们研究了在一个机构中 1995 年至 2015 年期间接受手术切除的 80 例 pNEN 患者的肿瘤进展预测因素。在多变量分析中,与 PFS 相关的两个独立变量是 Ki-67(HR 2.97;95%CI 1.26-7.02)和同步肝转移的存在(HR 3.60;95%CI 1.70-7.61)。使用 Ki-67<3%和 M0 作为参考,Ki-67 为 3-20%的 M0 患者、Ki-67≤20%的 M1 患者和 Ki-67>20%的患者肿瘤进展的 HR 分别为 3.21(95%CI 1.18-8.74)、5.06(2.29-11.2)和 24.3(6.64-89.2)。在任何分析中,肿瘤大小(≤2cm 与>2cm)都不是预测因素。术前活检与手术标本的 Ki-67 值的组内相关系数为 0.99,97%的活检正确识别了 Ki-67 分级。Ki-67 和肝转移的存在是 pNEN 的主要预后因素,无论肿瘤大小如何,它们都能识别出不同的进展风险。对于直径为 1-2cm 的肿瘤患者,应包括术前 pNEN 活检进行 Ki-67 评估,以帮助决定是否进行手术切除。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验